Tokyo Tape
Sign in
← Kawaguchi Chemical Industry

Quarterly report · Q2

4361.TEDINET S100OO05
Period2021-12-01 → 2022-05-31
Filed2022-07-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥3.9bn2021-12-01 → 2022-05-31Cons.Net sales
Revenue¥7.9bn2020-12-01 → 2021-11-30Cons.Net sales (5-year summary)
Revenue¥3.9bn2020-12-01 → 2021-05-31Cons.Net sales
Operating income¥226m2021-12-01 → 2022-05-31Cons.Operating income
Operating income¥270m2020-12-01 → 2021-05-31Cons.Operating income
Ordinary income¥235m2021-12-01 → 2022-05-31Cons.Ordinary income
Ordinary income¥386m2020-12-01 → 2021-11-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥273m2020-12-01 → 2021-05-31Cons.Ordinary income
Profit before tax¥234m2021-12-01 → 2022-05-31Cons.Income before income taxes
Profit before tax¥273m2020-12-01 → 2021-05-31Cons.Income before income taxes
Net income (owners)¥179m2021-12-01 → 2022-05-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥281m2020-12-01 → 2021-11-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥195m2020-12-01 → 2021-05-31Cons.Profit loss attributable to owners of parent
Net income¥179m2021-12-01 → 2022-05-31Cons.Profit loss
Net income¥195m2020-12-01 → 2021-05-31Cons.Profit loss
Total assets¥7.8bnat 2022-05-31Cons.Assets
Total assets¥7.9bnat 2021-11-30Cons.Assets
Total assets¥7.6bnat 2021-05-31Cons.Total assets (5-year summary)
Total liabilities¥5.4bnat 2022-05-31Cons.Liabilities
Total liabilities¥5.6bnat 2021-11-30Cons.Liabilities
Net assets / equity¥2.4bnat 2022-05-31Cons.Net assets
Net assets / equity¥2.3bnat 2021-11-30Cons.Net assets
Net assets / equity¥2.2bnat 2021-05-31Cons.Net assets (5-year summary)
Cash and deposits¥984mat 2022-05-31Cons.Cash and deposits
Cash and deposits¥1.3bnat 2021-11-30Cons.Cash and deposits
Cash & equivalents¥984mat 2022-05-31Cons.Cash and cash equivalents
Cash & equivalents¥1.3bnat 2021-11-30Cons.Cash and cash equivalents
Cash & equivalents¥1.1bnat 2021-05-31Cons.Cash and cash equivalents
Cash & equivalents¥883mat 2020-11-30dCons.Cash and cash equivalents
Operating cash flow−¥124m2021-12-01 → 2022-05-31Cons.Net cash provided by used in operating activities
Operating cash flow¥785m2020-12-01 → 2021-11-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥388m2020-12-01 → 2021-05-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥121m2021-12-01 → 2022-05-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥246m2020-12-01 → 2021-11-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥109m2020-12-01 → 2021-05-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥104m2021-12-01 → 2022-05-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥119m2020-12-01 → 2021-11-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥78m2020-12-01 → 2021-05-31Cons.Net cash provided by used in financing activities
EPS (basic)¥147.062021-12-01 → 2022-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥68.822022-03-01 → 2022-05-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥230.992020-12-01 → 2021-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥160.32020-12-01 → 2021-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥95.622021-03-01 → 2021-05-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio30.6%at 2022-05-31Cons.Equity to asset ratio (5-year summary)
Equity ratio28.5%at 2021-11-30Cons.Equity to asset ratio (5-year summary)
Equity ratio28.5%at 2021-05-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2021-12-01 → 2022-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2021-12-01 → 2022-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2021-12-01 → 2022-05-31¥211m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2021-12-01 → 2022-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2021-12-01 → 2022-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2021-12-01 → 2022-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2021-12-01 → 2022-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-12-01 → 2022-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-12-01 → 2022-05-31¥226m
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2020-12-01 → 2021-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2020-12-01 → 2021-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2020-12-01 → 2021-05-31¥255m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2020-12-01 → 2021-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2020-12-01 → 2021-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2020-12-01 → 2021-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2020-12-01 → 2021-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2020-12-01 → 2021-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2020-12-01 → 2021-05-31¥270m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 477
ItemContextValueUnit
Other nclPrior1YearInstant125924000JPY
Other nclCurrentQuarterInstant135481000JPY
Noncurrent liabilitiesPrior1YearInstant1106672000JPY
Noncurrent liabilitiesCurrentQuarterInstant1052706000JPY
LiabilitiesPrior1YearInstant5641705000JPY
LiabilitiesCurrentQuarterInstant5402887000JPY
Capital stockPrior1YearInstant610000000JPY
Capital stockCurrentQuarterInstant610000000JPY
Capital surplusPrior1YearInstant58437000JPY
Capital surplusCurrentQuarterInstant58437000JPY
Retained earningsPrior1YearInstant1528465000JPY
Retained earningsCurrentQuarterInstant1646636000JPY
Treasury stockPrior1YearInstant-8067000JPY
Treasury stockCurrentQuarterInstant-8067000JPY
Shareholders equityPrior1YearInstant2188836000JPY
Shareholders equityCurrentQuarterInstant2307006000JPY
Valuation difference on available for sale securitiesPrior1YearInstant42413000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant36984000JPY
Foreign currency translation adjustmentPrior1YearInstant21325000JPY
Foreign currency translation adjustmentCurrentQuarterInstant34642000JPY
Valuation and translation adjustmentsPrior1YearInstant63739000JPY
Valuation and translation adjustmentsCurrentQuarterInstant71626000JPY
Net assetsPrior1YearInstant2252575000JPY
Net assetsCurrentQuarterInstant2378633000JPY
Liabilities and net assetsPrior1YearInstant7894280000JPY
Liabilities and net assetsCurrentQuarterInstant7781521000JPY
Net salesPrior1YTDDuration3882808000JPY
Net salesCurrentYTDDuration3946010000JPY
Cost of salesPrior1YTDDuration3043241000JPY
Cost of salesCurrentYTDDuration3148143000JPY
Gross profitPrior1YTDDuration839566000JPY
Gross profitCurrentYTDDuration797867000JPY
Selling general and administrative expensesPrior1YTDDuration569631000JPY
Selling general and administrative expensesCurrentYTDDuration571571000JPY
Operating incomePrior1YTDDuration269934000JPY
Operating incomeCurrentYTDDuration226296000JPY
Interest income noiPrior1YTDDuration393000JPY
Interest income noiCurrentYTDDuration1034000JPY
Dividends income noiPrior1YTDDuration734000JPY
Dividends income noiCurrentYTDDuration1246000JPY
Reversal of allowance for doubtful accounts noiPrior1YTDDuration－JPY
Reversal of allowance for doubtful accounts noiCurrentYTDDuration89000JPY
Foreign exchange gains noiPrior1YTDDuration6797000JPY
Foreign exchange gains noiCurrentYTDDuration9057000JPY
Insurance income noiPrior1YTDDuration1064000JPY
Insurance income noiCurrentYTDDuration－JPY
Compensation income noiPrior1YTDDuration－JPY
Compensation income noiCurrentYTDDuration2384000JPY
Other noiPrior1YTDDuration3438000JPY
Other noiCurrentYTDDuration4212000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2021-11-30pass
balance sheet identityconsolidated 2022-05-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-11-30pass
statement vs summary · net assetsconsolidated 2022-05-31pass
statement vs summary · net income attributable to parentconsolidated 2020-12-01/2021-05-31pass
statement vs summary · net income attributable to parentconsolidated 2021-12-01/2022-05-31pass
statement vs summary · operating cash flowconsolidated 2020-12-01/2021-05-31pass
statement vs summary · operating cash flowconsolidated 2021-12-01/2022-05-31pass
statement vs summary · revenueconsolidated 2020-12-01/2021-05-31pass
statement vs summary · revenueconsolidated 2021-12-01/2022-05-31pass
statement vs summary · total assetsconsolidated 2021-11-30pass
statement vs summary · total assetsconsolidated 2022-05-31pass